On November 28, Innovent Biologics Inc. (hereinafter referred to as " Innovent Biologics "), a Hong Kong-listed company, announced that its independently developed product, Xinmeiyue® (piconzimab injection), has been approved by the National Medical Products Administration (NMPA) for use in adult patients with moderate to severe plaque psoriasis who are suitable for systemic therapy.
As the first IL-23p19-targeted monoclonal antibody drug independently developed by a domestic company in China, the launch of Xinmeiyue® marks a new stage in the precision treatment of psoriasis in China.
Psoriasis is an immune-mediated, chronic, relapsing, inflammatory, and systemic disease induced by the interaction between the individual and the environment, characterized by recurrent flare-ups and lifelong management. Patients typically present with erythema, scales, and plaques on the skin, which may also affect the scalp, nails, palms, and soles, impacting appearance, sleep, social interactions, and emotional state.
It is estimated that there are over 7 million psoriasis patients in China, with plaque psoriasis being the most common, and about 30% of them suffering from moderate to severe cases. Although there is currently no cure, selecting more effective and individualized treatment plans is crucial for controlling the disease, reducing the risk of comorbidities, maintaining long-term efficacy, and comprehensively improving quality of life.

https://finance.eastmoney.com/a/202511283577957167.html